M&A
confidence high
sentiment positive
materiality 0.75
Arcellx closes collaboration with Kite/Gilead for CART-ddBCMA; sells $100M of stock to Gilead
Arcellx, Inc.
- Global collaboration to co-develop and co-commercialize CART-ddBCMA for relapsed/refractory multiple myeloma.
- CART-ddBCMA is in Phase 2 pivotal trial; companies will co-commercialize in U.S., Kite outside U.S.
- Arcellx sold 3,478,261 shares of common stock to Gilead for aggregate ~$100M.
- Closing followed expiration of HSR waiting period; deal previously disclosed in December 2022.